| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb12a064f514f0876c511fc78fbabcad |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-265
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C309-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C309-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate |
2017-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6442a72cc80a1d30e7079f5cc4db295e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30326d9a8ddb91ca6cec7d47fb6ab006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_630a1bdeef38b07710ab3666508ffd88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_284063a298dca5736c0537e44fec074c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2df284d6eeeae51de46d2109dd58fa48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72196b2961a3a5c639c303d280988137 |
| publicationDate |
2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112018075823-A2 |
| titleOfInvention |
n- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5 - ((4- (1-methyl-1h-indol-3-yl) pyrimidin-2-yl) amino) phenyl) pharmaceutical salts acrylamide and its crystalline forms |
| abstract |
n- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5 - ((4- (1-methyl-1h-indol-3-yl) pyrimidin-2-yl) amine) phenyl) crystalline forms Acrylamide (1) and its pharmaceutically acceptable salts and compositions useful for the treatment or prevention of diseases or clinical conditions mediated by mutant forms of the epidermal growth factor receptor (eg epidermal growth factor receptor), such as various cancers, are disclosed. |
| priorityDate |
2016-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |